预约演示
更新于：2026-07-17
Baricitinib
巴瑞替尼
更新于：2026-07-17
概要
基本信息
药物类型 小分子化药 |
别名 Baricitinib (JAN/USAN/INN)、巴瑞克替尼、INCB 028050 + [11] |
作用方式 抑制剂 |
作用机制 JAK1抑制剂(酪氨酸蛋白激酶JAK1抑制剂)、JAK2抑制剂(酪氨酸蛋白激酶JAK2抑制剂) |
原研机构 |
非在研机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评突破性疗法 (美国)、快速通道 (美国)、紧急使用授权 (美国)、孤儿药 (美国)、特殊审批 (中国)、孤儿药 (日本)、优先审评 (美国) |
登录后查看时间轴
结构/序列
分子式C16H17N7O2S |
InChIKeyXUZMWHLSFXCVMG-UHFFFAOYSA-N |
CAS号1187594-09-7 |
关联
280
项与 巴瑞替尼 相关的临床试验CTIS2026-525221-21-01
Optimising Arthritis Strategies in Elderly patients (≥70 years) with rheumatoid arthritis in sustained low disease activity (the OASE study): A Prospective Target Trial Emulation Study Evaluating Tapering of Disease-Modifying Anti-Rheumatic Drugs vs. Usual Care Based on Patient Preference
NCT07543458
A Randomised Platform Trial to Evaluate Therapeutics in Patients With Moderate or Severe Dengue (DEN-HOST)
NCT07262983
A Pilot Study to Evaluate the Safety and Tolerability of Baricitinib in Patients With Job s Syndrome With Lupus-like Disease and/or Atopic Dermatitis
100 项与 巴瑞替尼 相关的临床结果
登录后查看更多信息
100 项与 巴瑞替尼 相关的转化医学
登录后查看更多信息
100 项与 巴瑞替尼 相关的专利（医药）
登录后查看更多信息
3,726
项与 巴瑞替尼 相关的文献（医药）2026-12-31ANNALS OF MEDICINE
JAK inhibitor tofacitinib alleviates secretory dysfunction and Th17/Treg imbalance in a Sjögren’s disease murine model
Article
作者: Xu, Jianghan ; Ou, Yanjing ; Zhou, Lin ; Wu, Dong ; He, Kaixun ; Lin, Yanjun ; Su, Jingjing ; Liu, Chaowei ; Chen, Jiang
OBJECTIVES:
To examine whether the JAK inhibitor tofacitinib alleviates secretory dysfunction and modulates Th17/Treg balance in a Sjögren's disease (SjD) murine model.
METHODS:
Integrated analysis of SjD transcriptome sequencing (GSE159574, GSE247662) identified key signalling pathways, potential therapeutic agents, and immune cell infiltration. NOD/ShiLtj mice were administered with or without tofacitinib. Secretory function and inflammation were assessed via fluorescein ocular surface staining, tear flow rate, histopathology (HE, Masson, Sirius Red), saliva flow rate, immunohistochemistry, immunofluorescence, flow cytometry, and cytokine measurement. Pearson's linear regression evaluated the correlation between Th17/Treg balance and secretory function.
RESULTS:
Bioinformatics analysis showed the JAK-STAT pathway and CD4+ T cells contribute to SjD pathogenesis. Tofacitinib reduced corneal fluorescein staining, increased tear break-up time and secretion, diminished salivary gland lymphocytic inflammation, improved saliva flow rate, and altered phospho-JAK3-STAT1 expression. It also reduced Th17 cell proportion, increased Treg cell proportion in salivary glands and spleens, decreased IL-17, and increased IL-10 and TGF-β in blood. A strong negative correlation existed between secretory function and Th17/Treg balance.
CONCLUSIONS:
Tofacitinib potently attenuated secretory dysfunction and inflammation in SjD mice, possibly by modulating Th17/Treg balance, suggesting it may be a therapeutic agent for SjD.
2026-12-31JOURNAL OF DERMATOLOGICAL TREATMENT
Management of adult vitiligo: approved topical JAK inhibitor and standard therapies
Review
作者: Perrotta, Nicola ; Cantisani, Carmen ; Greco, Maria Elisabetta ; Proietti, Ilaria ; Caro, Alberto di ; di Guardo, Antonio ; Sasso, Francesca Paola ; Potenza, Concetta ; Pellacani, Giovanni ; Fiorito, Luigi Angelo ; Feresin, Francesca ; Nisticò, Steven Paul ; Dattola, Annunziata
INTRODUCTION:
Vitiligo is a chronic autoimmune depigmenting disorder. Ruxolitinib 1.5% cream is currently the only therapy specifically approved for its treatment. In addition, clinical guidelines recommend off label standard therapies, including topical corticosteroids (TCS), topical calcineurin inhibitors (TCI), phototherapy (narrowband UVB or excimer devices), and selected off-label systemic regimens.
MATERIALS AND METHODS:
This review summarizes the scientific evidence on approved and guideline-recommended treatments for adult vitiligo, using a PRISMA-based approach. Only English-language articles published between 2000 and 2025 were included. Interventions comprised approved therapies and standard treatments recommended by guidelines. Outcomes evaluated were changes in Facial and Total Vitiligo Area Scoring Index (F-VASI/T-VASI), quality of life, and safety. Risk of bias was assessed using the Risk of Bias 2 (RoB 2) tool for randomized controlled trials (RCTs) and the Risk of Bias in Non-randomized Studies of Interventions (ROBINS-I) for non-randomized studies.
RESULTS:
Ruxolitinib cream demonstrated superior F-VASI responses compared with vehicles in phase II-III RCTs. Evidence supports the efficacy of potent or very potent TCS, TCI, and NB-UVB or targeted 308-nm devices in localized disease.
CONCLUSION:
Systemic regimens show benefits in selected clinical scenarios, although supporting evidence remains heterogeneous. Treatment selection should be individualized based on disease activity, extent, anatomical site, and patient preferences.
2026-12-31ANNALS OF MEDICINE
Efficacy and safety of Ruxolitinib-based combination therapy in the patients with Myelofibrosis (MF): a systematic review and meta-analysis
Review
作者: Li, Yuxin ; Sun, Wanling ; Cao, Yaofang ; Hui, Wuhan ; Tan, Shuai
BACKGROUND:
Myelofibrosis (MF) is a chronic myeloproliferative neoplasm. Although Ruxolitinib, a JAK1/2 inhibitor, remains the cornerstone of MF treatment, it does not reverse disease progression, and resistance frequently emerges. These limitations have prompted investigation into combination therapies targeting pathways beyond the JAK-STAT axis. This meta-analysis aims to evaluate the efficacy and safety of Ruxolitinib-based combination therapies in patients with MF.
METHODS:
We conducted a systematic search of databases for studies published through August 1, 2025. Thirteen distinct Ruxolitinib-based combination regimens were included. Primary efficacy endpoints were ≥35% spleen volume reduction at 24 weeks (SVR35) and ≥50% reduction in total symptom score (TSS50). Safety endpoints focused on the incidence of grade 3/4 thrombocytopenia and anemia. Subgroup analyses were performed based on prior JAK inhibitor exposure and therapeutic mechanism of action.
RESULTS:
A total of 19 studies comprising 1,088 patients were included in the meta-analysis. Among JAK inhibitor-naïve patients, the combination of Ruxolitinib with Selinexor demonstrated the highest efficacy (SVR35: 92%; TSS50: 78%), followed by Ruxolitinib plus BMS-986158 (SVR35: 90%). For patients with prior JAK inhibitor exposure, Ruxolitinib plus Siremadlin (SVR35: 45%) showed notable activity.
CONCLUSION:
For JAK inhibitor-naïve patients, Ruxolitinib-based combination regimens demonstrated satisfactory clinical responses and the potential for meaningful disease control. For patients with prior JAK inhibitor exposure, the addition of combination therapy drugs may further enhance the efficacy. Personalized treatment selection remains essential, as therapeutic efficacy is significantly influenced by prior JAK inhibitor exposure.
100 项与 巴瑞替尼 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 附着点炎相关关节炎 | 欧盟 | 2023-09-21 | |
| 附着点炎相关关节炎 | 冰岛 | 2023-09-21 | |
| 附着点炎相关关节炎 | 列支敦士登 | 2023-09-21 | |
| 附着点炎相关关节炎 | 挪威 | 2023-09-21 | |
| 幼年特发性关节炎 | 欧盟 | 2023-09-21 | |
| 幼年特发性关节炎 | 冰岛 | 2023-09-21 | |
| 幼年特发性关节炎 | 列支敦士登 | 2023-09-21 | |
| 幼年特发性关节炎 | 挪威 | 2023-09-21 | |
| 少关节关节炎 | 欧盟 | 2023-09-21 | |
| 少关节关节炎 | 冰岛 | 2023-09-21 | |
| 少关节关节炎 | 列支敦士登 | 2023-09-21 | |
| 少关节关节炎 | 挪威 | 2023-09-21 | |
| 多关节型幼年特发性关节炎 | 欧盟 | 2023-09-21 | |
| 多关节型幼年特发性关节炎 | 冰岛 | 2023-09-21 | |
| 多关节型幼年特发性关节炎 | 列支敦士登 | 2023-09-21 | |
| 多关节型幼年特发性关节炎 | 挪威 | 2023-09-21 | |
| 新型冠状病毒感染 | 瑞士 | 2017-06-19 | |
| 斑秃 | 欧盟 | 2017-02-13 | |
| 斑秃 | 冰岛 | 2017-02-13 | |
| 斑秃 | 列支敦士登 | 2017-02-13 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 1型糖尿病 | 临床3期 | 美国 | 2026-01-12 | |
| 1型糖尿病 | 临床3期 | 日本 | 2026-01-12 | |
| 1型糖尿病 | 临床3期 | 澳大利亚 | 2026-01-12 | |
| 1型糖尿病 | 临床3期 | 比利时 | 2026-01-12 | |
| 1型糖尿病 | 临床3期 | 巴西 | 2026-01-12 | |
| 1型糖尿病 | 临床3期 | 加拿大 | 2026-01-12 | |
| 1型糖尿病 | 临床3期 | 芬兰 | 2026-01-12 | |
| 1型糖尿病 | 临床3期 | 法国 | 2026-01-12 | |
| 1型糖尿病 | 临床3期 | 德国 | 2026-01-12 | |
| 1型糖尿病 | 临床3期 | 以色列 | 2026-01-12 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 类风湿关节炎 RF | ACPA | 34 | 蓋繭襯鹹憲夢鑰製繭範(齋鹹遞鹽觸餘觸窪積鹽) = 積齋醖願築衊鬱襯網艱 製夢範簾壓鏇窪構襯鬱 (獵夢襯遞淵積醖繭窪襯 ) 更多 | 积极 | 2026-06-11 | ||
N/A | 33 | 膚願鹹觸鹽窪網窪積構(艱獵範簾構齋衊襯築壓) = 觸願鹹網觸壓蓋鑰膚醖 觸築範壓網齋簾願餘窪 (餘鹽鏇網憲憲淵廠遞繭, 4.5) 更多 | 积极 | 2026-06-11 | |||
膚願鹹觸鹽窪網窪積構(艱獵範簾構齋衊襯築壓) = 衊壓網觸窪艱艱餘鑰顧 觸築範壓網齋簾願餘窪 (餘鹽鏇網憲憲淵廠遞繭, 6.7) 更多 | |||||||
临床4期 | 3,640 | 選鑰製獵遞艱獵簾醖窪(獵鬱鹹鬱獵餘鹹製選醖) = 觸獵選蓋蓋膚繭襯鬱憲 築蓋膚餘餘簾製範鏇衊 (鬱襯顧餘淵製壓構襯獵 ) 更多 | 非劣 | 2026-06-11 | |||
TNFi (adalimumab or etanercept) | 選鑰製獵遞艱獵簾醖窪(獵鬱鹹鬱獵餘鹹製選醖) = 簾鏇繭簾夢觸窪簾醖憲 築蓋膚餘餘簾製範鏇衊 (鬱襯顧餘淵製壓構襯獵 ) 更多 | ||||||
N/A | 372 | 積蓋鏇網簾範齋壓鏇繭(願醖積膚窪鬱繭觸夢獵) = 蓋壓願顧蓋製淵製獵鏇 蓋鬱憲遞觸遞範夢選簾 (獵夢糧窪觸齋願齋膚襯 ) | 积极 | 2026-06-11 | |||
積蓋鏇網簾範齋壓鏇繭(願醖積膚窪鬱繭觸夢獵) = 願鑰醖顧夢範淵鹽鏇築 蓋鬱憲遞觸遞範夢選簾 (獵夢糧窪觸齋願齋膚襯 ) | |||||||
N/A | 185 | 獵鹹繭餘製艱淵鑰製鹹(廠衊艱簾願壓簾獵膚廠) = Transient abdominal pain and other gastrointestinal symptoms were most frequent adverse event in all agents. 築簾獵憲觸鹽糧蓋廠築 (蓋簾醖艱選顧獵範積鏇 ) 更多 | 积极 | 2026-06-11 | |||
临床3期 | 46 | 艱壓鑰顧鹹夢膚壓蓋廠(窪糧繭積鑰膚選積廠鹽) = 選觸齋膚構顧壓廠鹹鑰 蓋襯齋壓鏇餘鬱鏇膚鹽 (顧鹽蓋簾壓醖壓齋範遞 ) 更多 | 积极 | 2026-06-11 | |||
Placebo + Glucocorticoids | 艱壓鑰顧鹹夢膚壓蓋廠(窪糧繭積鑰膚選積廠鹽) = 齋壓鬱網選鬱製夢遞鏇 蓋襯齋壓鏇餘鬱鏇膚鹽 (顧鹽蓋簾壓醖壓齋範遞 ) 更多 | ||||||
临床3期 | 20 | (Black patients) | 淵鏇遞遞窪襯膚顧簾顧(齋窪積鏇簾鑰築夢網繭) = 願遞鑰範淵壓廠蓋觸衊 簾醖鬱襯齋願襯遞憲遞 (鏇製繭遞襯淵繭壓鹹糧 ) 更多 | 积极 | 2026-03-27 | ||
N/A | 129 | 蓋範鹽觸鹽蓋膚範獵廠(構築艱廠鏇廠遞齋襯壓) = 繭壓網簾齋網膚鑰淵獵 齋願選憲鹽壓遞壓遞醖 (構壓築廠積遞積網襯憲 ) 更多 | 不佳 | 2026-03-27 | |||
鹽憲願築選壓獵鬱觸遞(製餘糧積觸鬱獵遞齋壓) = 遞淵淵選鹽襯廠衊艱糧 積積憲醖製網遞憲蓋鏇 (鹽鑰積獵繭窪鹹製築齋 ) | |||||||
N/A | 329 | 齋夢築醖窪築觸糧獵鹹(衊鏇壓鏇糧鏇獵製觸衊) = Tofacitinib was associated with shingles, acneiform eruptions, infections, gastrointestinal symptoms, weight gain, and one case of multiple sclerosis. Ruxolitinib caused mild cytopenias and gastrointestinal issues; upadacitinib led to hair depigmentation; filgotinib caused acneiform eruptions. Safety data for ritlecitinib, abrocitinib, and deuruxolitinib were limited. 鹽膚艱艱獵壓獵鬱襯衊 (觸膚積襯蓋網鏇艱製願 ) | 积极 | 2026-03-27 | |||
N/A | 103,275 | 鏇醖窪築醖構窪衊簾糧(蓋願簾窪遞顧獵餘齋鑰) = median onset ranged from 103 to 358 days across drugs, with early-failure type pattern ( 31), indicating AE rates declined over time. Tofacitinib cumulative AE curve differed significantly from others (adj.p 3C2e-16). 膚範蓋網簾製壓繭簾願 (鹹遞構艱網蓋鏇積壓繭 ) 更多 | 积极 | 2026-03-27 | |||
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
芽仔
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用